Company

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Lisa Helbling serves as the Chief Financial Officer for ImmunoPrecise Antibodies. At ImmunoPrecise, she oversees financial and strategic management, including the company’s financial reporting and long-range business planning. Additionally, she supervises human resources and legal. She brings over thirty years of broad experience in accounting, finance, enterprise risk management, audit, and ESOPs. Currently, she serves on the board of directors for Healthy Dakota Mutual Holdings and Blue Cross Blue Shield of North Dakota and is the Chair of the Audit & Compliance Committee. Prior to joining the executive team, Ms. Helbling served as CFO at Anchor Ingredients and TMI Hospitality, as well as VP of Internal Audit and Business Risk Management at Otter Tail Corporation.

Dr. Stefan Lang joined ImmunoPrecise in October 2019 as the Chief Business Officer. He is responsible for corporate and business development initiatives, as well as corporate and product strategic planning. He holds a Dr. rer. nat. in biology from the Technical University Karlsruhe, Germany, and a diploma in biology from the University of Kassel, Germany. He started his career as a technical consultant and moved into the biotech industry in 2000.

Dr. Lang has an impressive breadth of leadership within the biotech industry, including experience working at the organizational level and as a globally-recognized and respected leader in antibody business development.

In his most recent role, Dr. Lang worked in an executive role at Aldevron LLC, as the Vice President of Business Development, with his main focus on corporate strategy, R&D innovation, sales and business development. Prior to Aldevron, he worked at GENOVAC, a pioneer in genetic immunization for antibody generation.

As the Chief Technology Officer of ImmunoPrecise Antibodies, Chip Wheelock is responsible for overseeing information technology aspects of the company. Mr. Wheelock works closely with the other members of the Executive Management team, and unit business leaders, to grow the company through the use of software and technology services.

Mr. Wheelock brings a diverse background to ImmunoPrecise. He has held leadership positions within the software development and services industries over the past 25 years. His responsibilities encompassed global ERP deployments, cloud transformations and building a strategic line of business applications. Mr. Wheelock’s experience includes 16 years at Microsoft in various roles, and drove strategic and technical initiatives for many large organizations. Chip holds a bachelor’s degree from the University of Kansas along with several industry and project management certifications.

Kari Graber serves as the Vice President of Client Relations and Project Management for ImmunoPrecise Antibodies, and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.

Jason Orloske serves as the Vice President of Operations for ImmunoPrecise, and is responsible for operationalizing strategic initiatives and helping drive growth. Mr. Orloske is a transformational business leader with 20 years’ experience in project portfolio management and strategic delivery. He partners with IPA management to initiate, plan, design, monitor and control global projects, while ensuring they align with ImmunoPrecise’s vision.

Mr. Orloske brings a diverse background to ImmunoPrecise. Most recently, he led implementation management at WEX Health (health benefits SaaS platform), and Aldevron LLC, where he headed the North Dakota project management office. He holds a master’s degree in Project Management.

Dr. Debby Kruijsen is the General Manager of ImmunoPrecise Antibodies Europe, formerly ModiQuest Research (Oss, The Netherlands), which became part of the ImmunoPrecise family of companies in April 2018.

She began her career in immunology at Utrecht University in the Netherlands. In 2012, she joined ModiQuest Research where she held different scientific and management positions until she became General Manager of ImmunoPrecise Antibodies Europe. Dr. Kruijsen works closely with the executive and global teams to develop and execute business strategies, improve operational efficiencies, and support ImmunoPrecise as an innovative company in the CRO space.

Teri Otto is the General Manager of ImmunoPrecise Antibodies Canada (Victoria, BC). She works closely with the executive and internal teams to implement best practices and company strategy. Ms. Otto has held a variety of scientific and management positions prior to her role as General Manager.

Teri holds a Bachelor of Science in Microbiology and Associate degrees in Psychology and Applied Chemistry/Biochemistry.

Dr. Martin Hessing is the General Manager and co-founder of U-Protein Express (Utrecht, The Netherlands), which became part of the ImmunoPrecise family of companies in September 2017. He has a background in Biochemistry and Hematology-Immunology from Utrecht University and held postdoc positions at Kyushu University, in Japan, and Sanquin, in Amsterdam. He obtained work and management experience at the TNO-Nutrition and Food Research Institute as well as at Organon Teknika (now Biomerieux). In 2000, he co-founded AM-Pharma BV, a biopharmaceutical company specializing in anti-infectives and sepsis. In addition, Dr. Hessing was co-founder of BiOrion BV, Microdish, SERPINx and U-PACT, and served in a number of other biotech start-up companies in various roles. He is co-author of over 50 peer-reviewed papers and seven patent applications.